The fate of drugs in pregnancy.
The response of mother and fetus/neonate to drugs administered to the pregnant woman is determined largely by drug disposition and elimination within and between mother and fetus. Physiological changes occurring in pregnancy may result in reduced plasma protein binding, an increase in the apparent volume of distribution, and more rapid metabolic and renal clearance of certain drugs than are usually found in non-pregnant women. The consequences are relevant for the peak concentration of drug achieved after a single dose, the half-life of the drug, and the drug concentration to which the fetus is exposed via the placenta. Drugs whose dosage may need to be altered in pregnancy include most anticonvulsants, lithium, digoxin, certain beta-blockers, ampicillin and cefuroxime; for drugs which have not been specifically investigated, no generalizations are possible. Very few drugs given in pregnancy fail to cross the placenta and, as a rule, drug molecules not bound to plasma protein diffuse along a concentration gradient to establish and maintain an equilibrium. Because movement of drug molecules is bidirectional, the placenta is the main portal of exit from, as well as entry to, the fetus. The pharmacological response of the fetus to drugs which it receives depends mainly on the unbound concentration of drug in fetal blood--unwanted effects seldom occur if the maternal dose is correct; exceptions include tetracycline, antithyroid drugs, coumarin anticoagulants, aspirin, indomethacin and cerebral depressant drugs (opiates, barbiturates and phenothiazines). The total (bound plus unbound) drug concentration on the fetal side of the placenta is usually lower than on the maternal side except where differences in blood pH and/or protein binding lead to 'trapping' of drug in the fetus; the latter phenomenon may prove hazardous after birth because of the neonate's limited capacity to eliminate drugs by metabolism and excretion.
Mucklow
J C
JC
D000305:Adrenal Cortex Hormones / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000378:metabolism; D000700:Analgesics / Q000378:metabolism; D014151:Anti-Anxiety Agents / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000378:metabolism; D000893:Anti-Inflammatory Agents / Q000378:metabolism; D000927:Anticonvulsants / Q000378:metabolism; D001569:Benzodiazepines; D004077:Digoxin / Q000378:metabolism; D005260:Female; D005333:Fetus / Q000378:metabolism*; D006801:Humans; D008094:Lithium / Q000378:metabolism; D008431:Maternal-Fetal Exchange / Q000187:drug effects*; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011247:Pregnancy
D000305:Adrenal Cortex Hormones; D000319:Adrenergic beta-Antagonists; D000700:Analgesics; D014151:Anti-Anxiety Agents; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D004364:Pharmaceutical Preparations; D001569:Benzodiazepines; D004077:Digoxin; D008094:Lithium